JATT III Acquisition Corp closes $69M IPO with full over-allotment
- JATT III Acquisition Corp closed its IPO on August 27, 2026, raising $69 million in gross proceeds.
- Underwriters fully exercised the over-allotment option, adding 900,000 shares to the initial 6 million.
- Shares began trading on the Nasdaq Global Market under the ticker symbol JTTT on August 26.
- Guggenheim Securities acted as the sole book-running manager for the biotech-focused SPAC.
- AI Biotechnology LLC and Vianti Capital Fund I indicated non-binding interest in future private placements.
*this image is generated using AI for illustrative purposes only.
JATT III Acquisition Corp announced the closing of its initial public offering on August 27, 2026, raising total gross proceeds of $69,000,000. The final amount includes the full exercise of the underwriters’ over-allotment option.
The company sold a total of 6,900,000 ordinary shares at an offering price of $10.00 per share. This figure comprises the initial 6,000,000 shares plus 900,000 additional shares issued pursuant to the over-allotment option.
Offering Structure and Trading
The ordinary shares began trading on the Nasdaq Global Market under the ticker symbol "JTTT" on August 26, 2026. Guggenheim Securities, LLC acted as the sole book-running manager for the transaction.
| Metric | Detail |
|---|---|
| Total Shares Sold | 6,900,000 ordinary shares |
| Offering Price | $10.00 per share |
| Gross Proceeds | $69,000,000 |
| Over-allotment Shares | 900,000 shares (fully exercised) |
| Ticker Symbol | JTTT |
| Exchange | Nasdaq Global Market |
A registration statement for the securities was declared effective by the U.S. Securities and Exchange Commission on August 25, 2026.
Strategic Focus and Management
JATT III Acquisition Corp is a blank check company formed to pursue a merger, amalgamation, or similar business combination. While it may target any industry, the company intends to focus primarily on healthcare-related businesses, with an emphasis on biotechnology and life sciences.
The management team plans to seek businesses utilizing data-driven approaches, including machine learning and computational biology, to improve therapeutic discovery. The company aims to provide these targets with access to public markets for funding development and strategic transactions.
Dr. Someit Sidhu serves as Chief Executive Officer and Chairman of the Board. Nicholas Fernandez is the Chief Financial Officer. The Board of Directors also includes Verender S. Badial, Arjun Goyal, Jonathon Kluft, and Christopher Staral.
The company is sponsored by JATT Ventures III L.P. It has not selected a specific business combination target nor engaged in substantive discussions with any potential target.
Investor Participation
The offering included participation from Adage Capital Partners, L.P., ADAR1 Capital, Affinity Asset Advisors, LLC, Columbia Threadneedle Investments, Deep Track Capital, Great Point Partners, LLC, Janus Henderson Investors, Nantahala Capital, RA Capital Management, Sirenia Capital Management LP, and Squadron Capital Management LLC, among other institutional investors.
AI Biotechnology LLC, an affiliate of Access Industries, Inc., and Vianti Capital Fund I, L.P., have indicated non-binding interests to participate in a private placement that may occur concurrently with the consummation of the Company’s initial business combination.
How might the current valuation trends in the biotechnology and life sciences sectors influence JATT III's ability to identify a target company that meets its $69 million capital threshold?
Given the non-binding commitments from AI Biotechnology LLC and Vianti Capital, what specific criteria will JATT III use to select a final business combination partner in the data-driven healthcare space?
What is the expected timeline for JATT III to complete its initial business combination, and how does this align with typical SPAC redemption rates in the current market environment?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
